inc discov market custom
protein use pharmaceut food ingredi
chemic market util
codeevolv
use codeevolv develop novel biotherapeut
reason report
initi coverag
new enzym discoveri serv backbon
sought pharma partner gsk nestl expect
continu deeper adopt major player industri
diversif key piec posit thesi well
creat signific sharehold valu come year
applic spread adjac industri look
pharma revenu continu ramp program food
line provid technolog servic valu
increas number industri drive stori long-
import disclosur analyst certif page report access current disclosur
stephen inc cover compani client may refer
develop nestl recent enter agreement potenti licens cdxss pre-clin pku therapi
valu pharma manufactur opportun per share assum penetr mil
valu food ingredi opportun per share assum penetr mil revenu
discov market custom
protein use pharmaceut food
ingredi chemic market util
also use codeevolv develop novel
type revenu
product revenu total sell protein
 revenu total protein screen
share
short interest float
mil cash debt
pro forma recent offer
compani document stephen inc
 guidancen/an/an/afirmratingtargetcraig hallum capit hc first analystsstephen one year price histori chart
guid
line consensu
revenue vs
consensu mil
sell-sid initi
recent result revenu breakdown summari financi
out-performance partnership januvia tate
lyle also growth among diversifi set custom
net
evid diversif four product
revenu grew thirteen product revenu
compani document stephen inc
mil except epsincom statement share total gross sg total oper net adj product gross enu expens expens sheet total debt- total stockhold statement stock-bas work capit oper invest financ total chang op dollar quarter consensu expect prior result consensu theexpect prior guid given march enuetot product enuer enu share mercknestlenovartist lyleexela protein kind develop
protein molecul made amino acid protein take mani form perform mani function biolog
chemic system develop sell three categori protein enzym chemic drug manufactur enzym
use therapeut enzym use diagnost applic
enzym chemic manufactur
enzym diagnost
simpl exampl catalyst
catalyst
fragranc etc creat
seri chemic
histori catalyst
use natur occur
enzym use diagnost next gener sequenc
hand enzym use amplifi
dna sequenc amplif process
first enzym develop dna ligas
key ingredi dna replic process
second enzym develop polymeras
also key dna replic process
two enzym use pcr
like produc road
enzym biotherapeut
enzym use metabol food cdxss lead pre-clin
candid enzym replac therapi pku
see page detail
addit pku pre-clin investig work
hand diseas area suspect also small
use technolog antibodi develop
compani document stephen inc
protein
protein sold gram
proposit protein
manufactur drug
diagnost
biocatalyst panel kit enabl
custom test current
chemic process determin
protein may
make effici lead-in
protein sale
merck sell protein materi
manufactur januvia
product revenu
tate lyle sell protein use
ingredi product rev
thirteen product gener
mil revenu
product revenu
one exist protein use
custom chemic process
custom own
protein ip make money
custom licens codeevolv
royalti back-end
tate lyle sign second
protein engin agreement
platform agreement
growth came
lipitor- hcv-relat
lipitor goe gener
growth also
virtual growth
mil gsk
nestl
start
rev
product revenu grow diversifi
past
codeevolv licens driven recent revenu back
end mileston royalti meaning opportun
compani document stephen inc
call launch coverag overweight/vol rate price target believ
posit creat signific sharehold valu come year codeevolv proven demand top
pharma compani applic spread adjac industri look pharma revenu continu ramp
program food diagnost therapeut develop begin take hold bottom line provid technolog
servic valu increas number industri drive stori long-term stage diversifi revenu growth
valuat valu share use sum-of-the-part three main end market ad valu
novel biotherapeut opportun page page detail valuat
invest nearli mil build platform
build better protein faster competit
gsk platform deal deliv mil combin up-front potenti nice back-end payment
addit codeevolv licens near-term catalyst
new opportun adjac industri
therapeut market pku other
increasingli diversifi stabl revenu base
higher percentag predict revenu
put togeth revenu scenario look attract
codeevolv technolog underpin everyth
codeevolv technolog work
codeevolv enabl creation new enzym via direct
determin perform requir new protein
scan librari public databas start candid
creat thousand mutat start protein candid
rapidli screen determin qualiti mutat
sequenc mutat
perform iter process get ideal enzym
step use uniqu combin proprietari technolog
softwar know-how
competit competit advantag
invest codeevolv
intern pharma team disadvantag
work silo aspect protein develop
requir cross-disciplin expertis dont
platformwhich sever licens codeevolv
parti enzym develop compani
novazym primarili focu industri agricultur
invest nearli mil last year
spend mix technolog personnel
knowhow togeth constitut codeevolv platform
think would take year million dollar
player catch today
spent hundr million dollar creat uniqu protein engin platform
compani document stephen inc
build protein result higher yield given
build protein produc fewer wast byproduct
three presidenti green chemistri award
larger enzym librari autom high-throughput
assay advanc bio-informat decreas
resourc requir novel enzym creation
advers
build protein better
presenc chemic
codeevolv enabl faster effici develop protein higher stabil activ
compani document stephen inc
scope deal
codeevolv protein engin platform
receiv mil licens fee three year period
front-end revenu plu right back end mileston
mil mil per project royalti futur protein
initi gsk may use codeevolv develop enzym use
drug manufactur diagnost start
gsk allow use platform drug discoveri
fee recogn tech-transf period mil /q
wave tech transfer mil payment
wave tech transfer mil payment
mil
mil
start back-
key licens agreement drove mil revenu potenti drive much time
compani document stephen inc
scope deal part
sinc provid protein use
commerci manufactur januvia sitagliptin receiv
mil annual licens fee plu product revenu sale protein
think line revenu grow gain access
addit januvia manufactur facil come year
bought non-exclus global perpetu licens
codeevolv protein engin platform develop enzym
chemic synthesi biotherapeut discoveri
receiv mil licens fee two year period front-end
revenu plu right back end mileston mil per
project royalti also first right refus
manufactur protein discov codeevolv
mil
suppli variou enzym year
includ intermedi boceprevir hcv
sign januvia suppli agreement rev start
extend enzym suppli agreement
complet wave codeevolv tech transfer
saw good growth protein sale manufactur januvia
start
start protein suppli agreement progress full mil codeevolv licens back-end option
compani document stephen inc
work secur new larg codeevolv licens
base histori up-front rang mil mil back-end option
expect sign anoth larg deal
histor share react favor day platform deal announc
gsk announc share
announc share
nestl announc share
sign mini codeevolv deal porton pharma solut porton licens biocatalyst librari high-
throughput screen enzym manufactur know-how receiv preferenti access actual engin technolog
instead full technolog in-hous porton top work small mid-siz pharma effect distribut arm
custom arent like candid stand-alon codeevolv licens get mil per year option back-end royalti
expect anoth codeevolv licens sometim event drive share immedi higher
compani document stephen inc
new opportun adjac market
major cdxss current revenu sell enzym use manufactur small molecul drug remain
promis market also find addit opportun enzym technolog use food ingredi
manufactur molecular diagnost use stand-alone therapi
bil market conserv
math bil enzym market
estim drug product
benefit enzym
estim like
share bil market
commerci product
phase product
estim enzym food
ingredi bil
compon within bil
contribut mil product
revenu via tate lyle
expect drive mil annual
revenu three year
address mil
expect revenu contribut
think mil annual revenu
opportun three year
nestl health scienc cdxss
view pku call option worth
per share risk adjust basi
work drug
candid expect
readi partner
lot headroom core pharma market signific addit opportun new adjac market
compani document stephen inc
new opportun adjac market molecular diagnost
mil market dna ligas mil
mix direct channel depend end user
market four enzym use diagnost
expect meaning revenu diagnost
opportun
think eight-digit annual revenu
opportun next three year impli mil
may partner reach academ market go direct
group potenti larg custom alreadi
valid cdxss first enzym expect revenu
product
enzym use molecular diagnost
molecular diagnost field test look specif sequenc dna biomark may indic presenc risk
diseas dna sequenc key part diagnost process sampl dna must amplifi method call pcr
enough sequenc enzym use pcr
first two enzym chase
sampl
expect mil annual product revenu diagnost opportun three year
mil time
amplif dna
readi sequenc
compani document stephen inc
new opportun adjac market food ingredi
ingredi direct input food eat exampl
enzym use catalyst produc certain food food
ingredi presenc final food
tate lyle cdxss first custom food ingredi
cdxss enzym requir pre-market approv
label gener regard gra
market size competit
estim enzym use food ingredi
product bil market grow compound-annual-growth-rate
unlik platform deal gsk nestl tate lyle
enlist cdxss help project-by-project basi tate lyle
food ingredi compani use enzym manufactur
process pay develop new enzym success
ip protein make money sell
gram tate lyle
dec enter exclus protein suppli
ingredi tate lyle enzym use product
one food ingredi start develop
protein back suppli product tate
 lyle sever year agreement formal
relationship product cdxss sell product mil
enter multi-year agreement tate
 lyle engin second enzym use product
one ingredi receiv mil mil up-front
payment cover cdxss cost project to-
date get on-go mil per year protein
readi use like earli success earn
product revenu think could best sell product
portfolio impli mil per year
expect annual product revenu larg food ingredi market next year
mordor intellig compani document stephen inc
new opportun adjac market
understand pku disord
phenylketonuria pku genet disord character defici
complet absenc phenylalanin hydroxylas pah enzym
respons metabol amino acid phenylalanin phe phe found
food contain protein pah enzym lack due pku
bodi unabl metabol phe build danger level blood stream
caus sever neurolog issu
bodi
bodi
phe react
pah enzym
defici
result
tyrosin
use
phe build
blood
pku preval data nutrit manag inherit metabol diseas metabol
univers note say develop world pku
diet must heavili limit intak food contain protein
supplement special pku protein formula
kuvan sapropterin biomarin approv
pku therapi mil revenu
synthet version cofactor pah enzym
receiv approv eu approv
kuvan work pku patient must
combin pku diet
peg-pal pegvalias biomarin inject biolog
enzym replac therapi pdufa date may
substitut defici pah enzym
pre-clin pku work done intrexon
rubiu synthet biolog erydel
pku genetically-inherit disord affect peopl europ treatment option
bloomberg financ compani document stephen inc
total populationpku prevalenceestim pku
new opportun adjac market
overview nestl relationship
scope deal part
nestl alreadi presenc pku vitaflo line
pku diet supplement babi formula snack sold
consum nestl presenc pku touch consum
healthcar provid
nestl health scienc found focus
therapeut role nutrit
mil
payment
start phase trial
nestl exercis option licens
initi agreement right licens
variou development approv mileston mil
part option licens
oct nestl health scienc acquir option licens
pre-clin pku product conduct
phase trial nestl option licens
molecul point nestl fulli respons
part right first negoti cdxss pipelin product
optimist addit biotherapeut discoveri beyond
 focu four metabol diseas area vote
confid nestl acquir right first negoti pipelin
part collabor jointli discov new protein codeevolv
nestl work togeth discov new protein
fit nestl consum care medic nutrit portfolio
receiv fee work plu opportun mileston
royalti success product
mil
low-double-digit
nestl platform deal pku out-licens drive near-term revenu give credibl cdxss opportun drug dev
compani document stephen inc
new opportun adjac market
put valu pku opportun
estim current global pku market
per-shar valu opportun
mil
scenario assum approv
base case scenario worth per
share risk-adjust basi
bil pku market
kuvan keep market share cdx-
captur non-kuvan piec
equat mil revenu use royalti
discount revenu rate
appli probabl approv
estim pku opportun worth per share risk-adjust basi
compani document stephen inc
royalti use discount pre-tax incom assum ep assum tax price-to-earnings probabilti drug per-shar mil commentscommentscommentskuvan assum keep market share assum keep market share assum keep market sharepeg-p assum get non-kuvan revenue assum get non-kuvan revenue assum get non-kuvan assum get non-kuvan revenue assum get non-kuvan revenue assum get non-kuvan revtot bearbasebul file non-kuvan say market address kuvan estim global pku assum market compound-annual-growth-rate
increasingli diversifi stabl revenu base
higher percentag predict revenu
spike
loss big
grant revenu
defin predict revenu product revenu
back-end revenu platform deal contractu
recur product revenu tend happen year year
oppos larg one-tim revenu
predictable/recur product back-end platform
revenu total prior year
specd commerci product phase
later pipelin
top three
repres
small custom
account
shell statin
major
revenu
went virtual
top
revenu
account
revenu
nearli revenu disappear sinc grown mil divers revenu
compani document stephen inc
put togeth revenu scenario look attract
revenu walk
net flat product rev
rough midpoint guid
think conserv
mil revenue growth mostli
increment tate lyle
gsk back-end
think product revenue guid
good line-of-sight
bulk growth
nestl growth
licens
assum start phase
model combin mil
gsk back-end plu
mil
model mil growth
 tie
addit pharma
secur team
alon
worth mil
revenu get gra
label ingredi
forecast revenu grow mil think beat estim base stronger product revenue growth
compani document stephen inc
put togeth revenu scenario look attract
revenu walk
growth ingredi
diagnost
revenu spool
roughli flat fall-off nestl
 fee off-set
anoth
tate
expect year
partnership well
gener
model next
larg codeevolv deal hit
thu fill hole
left nestl tate lyle
forecast revenu grow mil growth driven product revenu
compani document stephen inc
valu pharma opportun
believ pharma opportun worth per share
penetr year
note doubl digit growth peer ls tool average multipl
think pharmaceut manufactur enzym opportun worth per share
compani document stephen inc
pharma enzym market pharma enzym annual pharma discount compound-annual-growth-rate discount valu year valu year valu year valuat food ingredi opportun
valu food ingredi opportun
believ food ingredi opportun worth per share
penetr year
think food ingredi opportun worth per share
mordor intellig compani document stephen inc
food ingredi enzym market food ingredi enzym annual food ingredi discount compound-annual-growth-rate discount valu year valu year valu year valuat molecular diagnost opportun
valu molecular diagnost opportun
believ molecular diagnost ingredi opportun worth per share
penetr year
think molecular diagnost opportun worth per share
compani document stephen inc
molecular diagnost enzym market molecular diagnost annual molecuar diagnos discount compound-annual-growth-rate discount valu year valu year valu year valuat put togeth
target
valu pharma manufactur opportun per share assum penetr mil revenu year
valu food ingredi opportun per share assum penetr mil revenu year
valu molecular diagnost opportun per share assum penetr mil revenu year
valu pku opportun per share assum likelihood success eventu market share
put valu cdxss opportun develop addit biotherapeut
think worth per share
compani document stephen inc
catalyst risk
new codeevolv licens day
announc new partner gsk nestl share
anywher one day
dna ligas expect meaning contribut
revenu new dna ligas annual
tate lyle food enzym process
develop enzym tate lyle first enzym
develop gener mil mil revenu
believ enzym could drive north
pku pursu applic codeevolv
technolog drug develop nestl recent enter
agreement potenti licens cdxss pre-clin
pku therapi think pku opportun
worth per share risk adjust basi
product sale growth view product sale royalti
highest qualiti revenu stream given
rel predict stabil two iron
fire drive increment product revenu growth
next month dna ligas tate lyle
custom concentr diversifi revenu base
last five year revenu still remain concentr
rev nestl rev
novarti rev revenu one-
time natur tate lyle licens fee
tie specif big product like mrk januvia
drug patent expir much cdxss product sale tie
underli partner drug sale januvia biggest risk
patent expir note cdxss patient
januvia catalyst extend past januvia patent
expect get busi gener upon expir
still risk
codeevolv competit feel strong
competit lead evidenc recent high-profil platform
licens gsk nestl much cdxss competit
wild-typ enzym intern protein engin
competit underli drug product second area
competit one step remov
underli product cdxss enzym enabl product
januvia tate lyle food ingredi face competit
extent suffer would expect cdxss
deriv revenu suffer play
mrk hcv molecul boceprevir displac new
sofusbovir product cdxss relat intermedi product
sale went mil mil
compani document stephen inc
own mil share
join jun come mr nicol spent year senior
posit albermarl corpor maker engin specialti chemic prior
work hercul inc
mr nicol bachelor chemic engin polytechn institut nyu
mit
join aug respons financi manag compani
mr sangster year experi biotech life scienc industri includ
svp corpor strateg dev
svp
join oct svp corpor strateg develop
respons growth includ expans enzym product sale new codeevolv
licens build pipelin in-hous drug candid
prior mr aldridg found ran sirona therapeut ltd held senior
posit questcor pharmaceut xenom limit work industri mr
aldridg invest bank wilson htm invest group bear stern
join director biocatalysi chemic develop vice-president
 sinc
prior dr lalond held key job altu biolog inc vista chemic co
found
subsidiari
spun
staf
staf
agreement
shell biofuel
partner
produc
intermedi
oct
patent
ip
mil
wind
 agreement
shell renew
lipitor come
start product
januvia
door
came market
kill
licens
licens
tech transfer
gsk
tate lyle
tate
rev gsk
licens nestl
tate lyle
compani document stephen inc
inc incom statement except per share year end dec research develop revenue- revenu share arrang total product gross product gross research sell gener total oper oper incom interest incom less interest expense/ incom tax expens oper net one-tim item tax affected- gaap net gaap adj eps- fulli dilut share margin analysi gross gross gener analysi product develop gross gener incomenmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnet incomenmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmgaap epsnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmadj ep exclud non-core/non-recur expens exclud depreci amort stock-bas compensationsourc compani report stephen inc estim analyst drew jone balanc sheet
inc balanc sheet year end dec market restrict account receiv relat parti account recievable- prepaid expens current total current restrict lt market properti equip intang asset total liabilitiesaccount accru accru defer relat parti defer revenue- total current defer revenu net current relat parti defer revenu net current- long term total stockhold equitycommon addit paid-in accumul accumul total stockhold total liabil sourc compani report stephen inc estim analyst drew jone flow statement
inc statement year end dec activ net incom stock-bas depreci amort amort increas decreas current increas decreas current other- net oper invest activ capit increas decreas increas decreas certain long-term increas decreas long-term fix asset other- net invest financ activ chang debt- dividends- stock buybacks- chang sharehold other- net financ begin net increase/decreas end free less free compani report stephen inc estim analyst drew jone compani mention
analyst primarili respons prepar content report certifi view express report
accur reflect analyst person view subject compani secur ii part analyst compens
directli indirectli relat specif recommend view express analyst report
